|
|||||
|
|

Insurance holding company Globe Life (NYSE:GL) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.3% year on year to $1.52 billion. Its non-GAAP profit of $4.81 per share was 5.9% above analysts’ consensus estimates.
Is now the time to buy GL? Find out in our full research report (it’s free for active Edge members).
Globe Life’s third quarter results met Wall Street’s revenue expectations, supported by steady premium growth and margin expansion in both life and health insurance operations. Management attributed the performance primarily to improved mortality experience and successful assumption updates, which reduced policy obligations. CEO Frank Svoboda emphasized the company’s ability to serve the lower middle to middle income market, noting, “Our long-term experience and data in this market provide us a distinct competitive advantage.” Direct-to-consumer sales rebounded, aided by new underwriting technology that increased conversion rates, while exclusive agency channels maintained agent count growth, underpinning longer-term sales momentum.
Looking ahead, Globe Life’s guidance reflects expectations for continued premium growth, supported by agent expansion, direct-to-consumer technology investments, and stable administrative expense ratios. Management projects that recent recruiting initiatives and new sales platforms will improve agent productivity and sales growth in the exclusive agency channels. CFO Tom Kalmbach noted, “We anticipate that the rollout of our new worksite enrollment platform and recruiting CRM will drive higher productivity and support our sales outlook.” While recent mortality gains are expected to persist into 2026, the company remains cautious, citing potential claim seasonality and macroeconomic uncertainties.
Management pointed to several operational and market-specific drivers behind the quarter’s results, particularly improved underwriting margins and the impact of digital initiatives on sales conversion.
Globe Life’s outlook is driven by continued agent growth, technology-enabled sales processes, and sustained underwriting margin improvements across life and health segments.
In upcoming quarters, our team will watch for (1) sustained growth in exclusive agent recruitment and the impact of new recruiting technology, (2) the effectiveness of digital underwriting and enrollment platforms in driving direct-to-consumer and worksite sales, and (3) margin trends in health and life insurance as rate changes and assumption updates take effect. The execution of the Bermuda reinsurance affiliate and its contribution to excess cash flow will also be a key milestone.
Globe Life currently trades at $134.80, in line with $135.66 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free for active Edge members).
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| Oct-24 | |
| Oct-23 | |
| Oct-23 | |
| Oct-22 | |
| Oct-22 | |
| Oct-22 | |
| Oct-22 | |
| Oct-22 | |
| Oct-21 | |
| Oct-20 | |
| Oct-15 | |
| Oct-09 | |
| Oct-08 | |
| Oct-08 | |
| Oct-06 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite